Direct comparison of a simple blood test processed with the Parsortix system with invasive solid biopsy of the metastatic site delivers comprehensive gene expression analysis Leading US cancer center, the University of Southern California Norris Comprehensive Cancer Center presents data ...
Read More »Angle’s liquid biopsy ovarian cancer test could beat current standard
PharmaTimes by Selina McKee – UK liquid biopsy group Angle has released trial findings that indicate its Parsortix blood test has the potential to out-perform the current standard of care in detecting ovarian cancer. The company said headline results from ...
Read More »Parsortix selected by the European consortium to validate blood-based biomarkers for cancer
ANGLE plc, the specialist medtech company, is pleased to announce that it has been formally selected for CANCER-ID, the European consortium to validate blood-based biomarkers for cancer. CANCER-ID is a European consortium funded by the Innovative Medicines Initiative (IMI), with ...
Read More »